Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras-related protein Rab-39B is a member of the RAB family of small GTPases involved in intracellular vesicular trafficking. RAB39B is primarily expressed in the brain and regulates the trafficking of proteins such as glutamate receptor subunits (especially GluA2) and synaptic structure maintenance. Loss-of-function mutations in RAB39B are causally linked to X-linked intellectual disability, Parkinson’s disease, and autism spectrum disorder. RAB39B acts by interacting with effector proteins including PICK1 and modulating both AMPA and NMDA receptor localization, as well as regulating basal autophagy via the PI3K-AKT-mTOR signaling pathway. Research models indicate that targeting RAB39B pathways (e.g., with rapamycin for autophagy) can partially rescue cognitive and synaptic deficits associated with RAB39B deficiency, but direct targeting in humans for therapy remains experimental and is associated with notable neurodevelopmental risks.
Modulation of autophagy via mTOR inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras-related protein Rab-39B (RAB39B).